Search results
Results From The WOW.Com Content Network
Remestemcel, sold under the brand name Ryoncil, is an allogeneic bone marrow-derived mesenchymal stromal cell therapy used for the treatment of graft-versus-host disease. [1] [2] Remestemcel contains mesenchymal stromal cells, which are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. [3]
Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...
Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the US Food and Drug Administration (FDA). [13] The most common side effects include low levels of platelets and white blood cells, mouth sores, nausea, musculoskeletal pain, abdominal pain, vomiting, febrile ...
In October 2017, belumosudil was granted orphan drug status in the United States for treatment of people with chronic graft-versus-host disease. [ 13 ] Efficacy of belumosudil was evaluated in clinical trial NCT03640481, [ 14 ] a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic graft-versus-host ...
The drug approval is based on data from a late-stage study, which showed a 54% reduction in the volume of new abnormal bone formation in patients compared to standard of care.
The FDA has approved five hematopoietic stem-cell products derived from umbilical cord blood, for the treatment of blood and immunological diseases. [ 11 ] In 2014, the European Medicines Agency recommended approval of limbal stem cells for people with severe limbal stem cell deficiency due to burns in the eye.
In 2021, FDA approved Kerecis Omega3 SurgiBind, fish-skin for surgical use that is useful in plastic and reconstructive surgery. [7] The company was valued at more than 100 million euros in 2021. [19] Kereceis also works on medical research with the US Armed Forces and provides the grafts to branches of the military. [4] [20]